Bank Of Montreal Seagen Inc. Transaction History

Bank Of Montreal

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 01, 2023	BUY	$191.51 - $216.16 $22.9 Million - $25.8 Million	119,508 Added 76.22%	276,309 $58.6 Million
Q2 2023 Aug 02, 2023	BUY	$187.64 - $206.25 $18.4 Million - $20.2 Million	97,802 Added 165.77%	156,801 $30.2 Million
Q1 2023 Jun 13, 2024	BUY	$127.59 - $203.08 $6.91 Million - $11 Million	54,171 New	54,171 $11 Million
Q4 2022 Feb 01, 2023	SELL	$117.37 - $139.17 $3.95 Million - $4.69 Million	-33,664 Reduced 36.33%	58,999 $7.58 Million
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $2.59 Million - $3.45 Million	19,176 Added 26.09%	92,663 $12.8 Million

Q2 2022 Aug 11, 2022	SELL	$108.81 - $179.33 $542,744 - $894,498	-4,988 Reduced 6.36%	73,487 $13.2 Million
Q1 2022 May 12, 2022	SELL	$119.61 - $157.85 $1.52 Million - $2 Million	-12,678 Reduced 13.91%	78,475 $11.1 Million
Q4 2021 Feb 11, 2022	SELL	$142.57 - $190.86 $7.68 Million - $10.3 Million	-53,873 Reduced 37.15%	91,153 $14.5 Million
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $19.8 Million - $23.6 Million	-138,767 Reduced 48.9%	145,026 $24 Million
Q2 2021 Aug 12, 2021	BUY	$135.08 - $161.1 $38.3 Million - $45.7 Million	283,793 New	283,793 $45.3 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.